Clinical Trials for Ovarian Cancer

A Phase I, Open-label, Dose Finding, Safety, Tolerability and Exploratory Trial of THEO-260 Administered Via an Intraperitoneal Route in Patients With High Grade Serous or Endometrioid Ovarian Cancer

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Enrolling adult women with measurable, advanced high-grade serous or endometrioid ovarian/fallopian tube/primary peritoneal carcinoma that is platinum-resistant or platinum-refractory (ECOG 0–1, adequate organ function). Participants receive intraperitoneal THEO-260, an investigational oncolytic adenovirus that selectively replicates in tumor tissue to cause tumor cell lysis and immune activation, administered as 6 doses over ~2 weeks in sequential dose-escalation cohorts.

ClinicalTrials.gov ID: NCT07211659

A Phase 1/2a, Multi-Center, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Evidence of Antitumor Activity of JAB-30355 in Adult Patients With Advanced Solid Tumors Harboring TP53 Y220C Mutation

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults (≥18) with locally advanced or metastatic solid tumors harboring confirmed TP53 Y220C mutation, ECOG 0–1, with measurable disease and progression after ≥1 prior systemic therapy (excluding active CNS disease and significant cardiac/QT issues). Patients receive oral JAB-30355 monotherapy, a small-molecule mutant p53 (Y220C) reactivator that binds/stabilizes p53 toward a wild-type–like conformation to restore p53 transcriptional activity.

ClinicalTrials.gov ID: NCT06386146

A Phase 1 Dose-Finding and Dose-Expansion Study of KIVU-107 in Participants With Locally Advanced or Metastatic Solid Tumors

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with locally advanced or metastatic solid tumors refractory to standard therapy or without proven effective options receive KIVU-107, an investigational PTK7-directed antibody-drug conjugate carrying an exatecan/topoisomerase I inhibitor payload. The study includes dose escalation followed by expansion at the recommended dose, with eligibility requiring measurable disease, ECOG 0–1, and adequate organ function.

ClinicalTrials.gov ID: NCT07229313

An Open-Label, Multicenter Study Evaluating the Safety, Efficacy, and Pharmacokinetics of IDE034 in Adult Participants With Locally Advanced/Metastatic Solid Tumors

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with ECOG 0–1 and measurable locally advanced/metastatic solid tumors co-expressing B7-H3 and PTK7, after progression/intolerance to prior therapy or lacking standard options, including NSCLC, ESCC, endometrial, ovarian, HNSCC, TNBC, colorectal, and CRPC. All participants receive IDE034, an investigational bispecific B7-H3/PTK7 antibody–drug conjugate with a topoisomerase I inhibitor payload, in dose-escalation and expansion cohorts.

ClinicalTrials.gov ID: NCT07503808

A Phase 1/1b Open-Label, Multicenter, First-in-Human Study Evaluating Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of RGT-490 as a Single Agent in Adult Subjects With Locally Advanced or Metastatic PIK3CA-Mutated Solid Tumors Including HR+/HER2- Breast Cancers

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Open-label dose-escalation/expansion study of oral RGT-490 monotherapy, a selective mutant PI3Kα inhibitor, in adults with locally advanced unresectable or metastatic solid tumors harboring activating PIK3CA mutations after at least one prior therapy. Expansion focuses on HR+/HER2− advanced breast cancer; patients with prior PI3Kα inhibitor exposure or diabetes requiring antihyperglycemic medication are excluded.

ClinicalTrials.gov ID: NCT07524322

A Phase 1, Multicenter, Open-Label, Dose-Escalation Study to Assess Safety, Tolerability, and Efficacy of EXS74539 as Monotherapy in Participants With Select Solid Tumors

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with ECOG 0–1 and measurable advanced selected solid tumors, including SCLC, extrapulmonary high-grade neuroendocrine/small-cell carcinomas, NSCLC, prostate, ovarian, renal, HNSCC, hepatic, gastric, and triple-negative breast cancers, after progression/relapse/intolerance to at least one standard systemic therapy. All patients receive dose-escalated oral EXS74539/REC-4539 monotherapy, a selective reversible LSD1/KDM1A epigenetic inhibitor, to define safety and MTD with preliminary efficacy assessment.

ClinicalTrials.gov ID: NCT07517198

A Phase 1 First-in-Human Study of PTK7-Directed Antibody Drug Conjugate HWK-007 in Participants With Advanced Solid Tumors

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with advanced/metastatic PTK7-expressing solid tumors, including non-squamous EGFR-wild-type NSCLC, platinum-resistant ovarian cancer, and endometrial carcinoma, receive HWK-007 IV every 3 weeks. HWK-007 is an investigational PTK7-directed antibody–drug conjugate delivering a topoisomerase I inhibitor payload, with dose escalation/expansion focused on safety, dose selection, pharmacokinetics, immunogenicity, and preliminary antitumor activity.

ClinicalTrials.gov ID: NCT07444814

A Phase I Study to Determine the Safety and Tolerability of BI 3820768 in Patients With Advanced Relapsed or Refractory Germ Cell Tumours, Endometrial Cancer, or Ovarian Cancer

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: First-in-human dose-escalation trial of injectable BI 3820768, an investigational immune-directed anticancer biologic with limited public target/mechanism details, given weekly for two 3-week cycles then every 3 weeks. Enrolls ECOG 0–1 adults with advanced relapsed/refractory germ cell tumors, endometrial cancer, or ovarian cancer after standard options; endometrial and ovarian cohorts require centrally confirmed target-positive tumors.

ClinicalTrials.gov ID: NCT07306559

A Phase 1 First-in-Human Study of MUC16-Directed Antibody Drug Conjugate HWK-016 in Participants With Advanced Solid Tumors.

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with advanced/metastatic solid tumors, initially ovarian cancer and endometrial carcinoma, receive IV HWK-016, a first-in-human MUC16-directed antibody–drug conjugate carrying a topoisomerase I inhibitor payload. Ovarian cancer cohorts may also receive HWK-016 combined with bevacizumab, with dose escalation/expansion focused on safety, recommended dose, pharmacokinetics, and preliminary antitumor activity.

ClinicalTrials.gov ID: NCT07470853

First in Human Phase 1 Study of AOH1996 in Patients With Refractory Solid Tumors

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: This trial involves adult patients with refractory solid tumors unresponsive or declining standard treatments, evaluating the PCNA inhibitor AOH1996, which targets a cancer-specific variant to impair DNA replication and repair, dosed orally twice daily in a 28-day cycle.

ClinicalTrials.gov ID: NCT05227326